Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 134Carcinoma, Non-Small-Cell Lung 133Prostatic Neoplasms 87Lung Neoplasms 43Neoplasms 31Squamous Cell Carcinoma of Head and Neck 30Neoplasm Metastasis 29Stomach Neoplasms 26Head and Neck Neoplasms 24Esophageal Neoplasms 20Parkinson Disease 4, Autosomal Dominant Lewy Body 17Pancreatic Neoplasms 17Ovarian Neoplasms 16Urinary Bladder Neoplasms 13Sarcoma 12Adenocarcinoma of Lung 9Triple Negative Breast Neoplasms 8Fallopian Tube Neoplasms 8Carcinoma, Transitional Cell 8Carcinoma, Ovarian Epithelial 8Adenocarcinoma Of Esophagus 7Recurrence 6Inflammatory Breast Neoplasms 5Carcinoma, Squamous Cell 5Carcinoma 5Breast Neoplasms, Male 5Adenocarcinoma, Bronchiolo-Alveolar 5Laryngeal Neoplasms 4Esophageal Squamous Cell Carcinoma 4Advanced Solid Tumors 4

Interventions

Trastuzumab 3Sugammadex 2Neostigmine 2Cisplatin 2valrubicin 1tucatinib 1pembrolizumab 1niraparib 1enfortumab vedotin 1avelumab 1atezolizumab 1Surveys and Questionnaires 1Sunitinib 1Standard of Care 1Rocuronium 1Pemetrexed 1Paclitaxel 1Nephroureterectomy 1Neoadjuvant Therapy 1Mitomycin 1Lymph Node Excision 1Glycopyrrolate 1Gemcitabine 1GSK-3326595 1Fulvestrant 1Docetaxel 1Cetuximab 1Afatinib 1Administration, Intravesical 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Urologic Neoplasms × Docetaxel × Clear all
NCT03636256 2023-08-14

Evaluation of NanoDoceĀ® in Participants With Urothelial Carcinoma

NanOlogy, LLC

Phase 1/2 Completed
36 enrolled 18 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urogenital Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔